Puma Biotechnology (PBYI) Cash & Current Investments (2011 - 2026)

Puma Biotechnology (PBYI) has 16 years of Cash & Current Investments data on file, last reported at $38.3 million in Q1 2026.

• Quarterly Cash & Current Investments fell 58.91% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.3 million (down 58.91% YoY) and the FY2025 annual result came in at $31.7 million, down 68.58% from the prior year.
• Cash & Current Investments advanced to $38.3 million in Q1 2026, from $31.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $107.2 million in Q1 2024 to a low of $31.7 million in Q4 2025.
• A 5-year average of $78.0 million and a median of $81.1 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments surged 50.47% — and 2025, when it tumbled 68.58%.
• Tracing PBYI's Cash & Current Investments over 5 years: stood at $81.1 million in 2022, then rose by 18.34% to $95.9 million in 2023, then rose by 5.24% to $101.0 million in 2024, then plunged by 68.58% to $31.7 million in 2025, then climbed by 20.67% to $38.3 million in 2026.
• The last three Cash & Current Investments figures came in at $38.3 million (Q1 2026), $31.7 million (Q4 2025), and $94.4 million (Q3 2025), per Business Quant data.